257 related articles for article (PubMed ID: 29521655)
1. Selexipag in Congenital Heart Disease-Associated Pulmonary Arterial Hypertension and Eisenmenger Syndrome: First Report.
El-Kersh K; Suliman S; Smith JS
Am J Ther; 2018; 25(6):e714-e715. PubMed ID: 29521655
[No Abstract] [Full Text] [Related]
2. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
[TBL] [Abstract][Full Text] [Related]
3. Use of the Prostacyclin Receptor Agonist Selexipag in Patients With Pulmonary Arterial Hypertension Associated With Eisenmenger Syndrome.
Demerouti EA; Karyofyllis P; Apostolopoulou SC
Can J Cardiol; 2021 Aug; 37(8):1286-1288. PubMed ID: 33539988
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Macitentan in Patients With Eisenmenger Syndrome.
Gatzoulis MA; Landzberg M; Beghetti M; Berger RM; Efficace M; Gesang S; He J; Papadakis K; Pulido T; Galiè N;
Circulation; 2019 Jan; 139(1):51-63. PubMed ID: 30586694
[TBL] [Abstract][Full Text] [Related]
5. [Evidence base for specific pulmonary vasodilators in adults with congenital heart disease].
Shmalts AA; Gorbachevsky SV
Ter Arkh; 2021 Sep; 93(9):1106-1116. PubMed ID: 36286872
[TBL] [Abstract][Full Text] [Related]
6. Single-Center Experience Using Selexipag in a Pediatric Population.
Gallotti R; Drogalis-Kim DE; Satou G; Alejos J
Pediatr Cardiol; 2017 Oct; 38(7):1405-1409. PubMed ID: 28702718
[TBL] [Abstract][Full Text] [Related]
7. A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension.
Sorensen LM; Wehland M; Kruger M; Simonsen U; Nassef MZ; Infanger M; Grimm D
Curr Pharm Des; 2017; 23(34):5191-5199. PubMed ID: 28891448
[TBL] [Abstract][Full Text] [Related]
8. New paradigm for pulmonary arterial hypertension treatment.
Tamura Y; Channick RN
Curr Opin Pulm Med; 2016 Sep; 22(5):429-33. PubMed ID: 27434819
[TBL] [Abstract][Full Text] [Related]
9. Eisenmenger syndrome: recent advances in pharmacotherapy.
Said S; Porres-Aguilar M; Porres-Munoz M; Mukherjee D
Cardiovasc Hematol Agents Med Chem; 2013 Dec; 11(4):289-96. PubMed ID: 24655213
[TBL] [Abstract][Full Text] [Related]
10. Selexipag for the treatment of pulmonary arterial hypertension.
Sharma K
Expert Rev Respir Med; 2016; 10(1):1-3. PubMed ID: 26567613
[TBL] [Abstract][Full Text] [Related]
11. Selexipag (Uptravi) for pulmonary arterial hypertension.
Med Lett Drugs Ther; 2016 Feb; 58(1488):21-3. PubMed ID: 26859660
[No Abstract] [Full Text] [Related]
12. Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.
Chin KM; Sitbon O; Doelberg M; Feldman J; Gibbs JSR; Grünig E; Hoeper MM; Martin N; Mathai SC; McLaughlin VV; Perchenet L; Poch D; Saggar R; Simonneau G; Galiè N
J Am Coll Cardiol; 2021 Oct; 78(14):1393-1403. PubMed ID: 34593120
[TBL] [Abstract][Full Text] [Related]
13. Selexipag: A Review in Pulmonary Arterial Hypertension.
Duggan ST; Keam SJ; Burness CB
Am J Cardiovasc Drugs; 2017 Feb; 17(1):73-80. PubMed ID: 27988834
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary arterial hypertension associated with a congenital heart defect: advanced medium-term medical treatment stabilizes clinical condition.
Duffels M; van Loon L; Berger R; Boonstra A; Vonk-Noordegraaf A; Mulder B
Congenit Heart Dis; 2007; 2(4):242-9. PubMed ID: 18377475
[TBL] [Abstract][Full Text] [Related]
15. Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study.
Hascoet S; Fournier E; Jaïs X; Le Gloan L; Dauphin C; Houeijeh A; Godart F; Iriart X; Richard A; Radojevic J; Amedro P; Bosser G; Souletie N; Bernard Y; Moceri P; Bouvaist H; Mauran P; Barre E; Basquin A; Karsenty C; Bonnet D; Iserin L; Sitbon O; Petit J; Fadel E; Humbert M; Ladouceur M
Arch Cardiovasc Dis; 2017 May; 110(5):303-316. PubMed ID: 28286190
[TBL] [Abstract][Full Text] [Related]
16. Selexipag for the treatment of pulmonary arterial hypertension.
Noel ZR; Kido K; Macaulay TE
Am J Health Syst Pharm; 2017 Aug; 74(15):1135-1141. PubMed ID: 28533253
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy in pulmonary veno-occlusive disease: time for a rethink?
Luo Q; Jin Q; Zhao Z; Zhao Q; Yu X; Yan L; Zhang Y; Xiong C; Liu Z
BMC Pulm Med; 2019 Dec; 19(1):257. PubMed ID: 31856792
[TBL] [Abstract][Full Text] [Related]
18. Use of selexipag in a child with pulmonary hypertension associated with sickle cell disease.
Das BB; Jadotte MM; Chan KC
J Heart Lung Transplant; 2020 Sep; 39(9):990-993. PubMed ID: 32418865
[No Abstract] [Full Text] [Related]
19. [Targeted therapy of pulmonary arterial hypertension (PAH)].
Klose H; Opitz C; Bremer H; Ewert R; Bonderman D; Rosenkranz S; Seeger W; Schmeißer A; Harbaum L; Buerke M; Ghofrani HA; Borst MM; Leuchte HH; Lange TJ; Behr J; Ulrich S; Lang I; Olschewski H; Gall H; Kabitz HJ; Kleber FX; Held M; Hoeper MM; Grünig E
Dtsch Med Wochenschr; 2014 Dec; 139 Suppl 4():S142-50. PubMed ID: 25489684
[No Abstract] [Full Text] [Related]
20. Selexipag for the treatment of pulmonary arterial hypertension.
Genecand L; Wacker J; Beghetti M; Lador F
Expert Rev Respir Med; 2021 May; 15(5):583-595. PubMed ID: 33382345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
